ArticleJournal of microscopy and ultrastructure
Gold Nanoparticles Down-Regulate Alpha Fetoprotein Expression Induced by Meloxicam Hepatotoxicity in Adult Male Albino Rats: Histological and Immunohistochemical Study.
Article in Journal of microscopy and ultrastructure. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Meloxicam is a non-steroidal anti-inflammatory drug most commonly used for the treatment of arthritis. Meloxicam decreases prostaglandin E2 resulting in an increase in free radical concentration within the cell. Alpha-fetoprotein (AFP) is a protein produced normally by the fetal liver in hepatoblasts. In inflammatory conditions, the adult liver synthesizes AFP by regenerating cells. Gold nanoparticles (AuNPs) in the medical field, represent one of the most commonly studied metal nanoparticles which have antioxidant properties. Objective: This study was conducted to evaluate the possible therapeutic effects of AuNPs on Meloxicam induced degenerative changes in rat liver. Materials and Methods: fifty adult male albino rats were divided into 8 groups: The first group (control); the AuNPs group was treated with AuNPs daily for 2 weeks. The MEL 2w& MEL 2m groups were treated with meloxicam daily for 2 weeks and 2 months respectively. The MEL2w+AuNPs & MEL2m+AuNPs groups received AuNPs for 2 weeks after meloxicam injection daily for 2 weeks and 2 months respectively. The MEL2w+SAL & MEL2m+SAL groups were given meloxicam for 2 weeks and 2 months respectively followed by saline injection for 2 weeks. Histological changes, AuNPs localization in the liver by silver nitrate stain, and AFP immunoexpression were studied. Results: Time dependent Degenerative changes and increased AFP expression were observed in the liver after meloxicam injection. However, AuNPs ameliorated these changes and decreased AFP expression. AuNPs were detected in Kupffer cells. Conclusion: AuNPs could ameliorate meloxicam-induced toxicity in the liver and decrease AFP expression because AuNPs act as free radical scavengers which accumulate in Kupffer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.